Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models

GAO Qi; HAN Yue; XU Wei; XU Jingjing; WANG Min; ZHANG Juan

doi:10.11665/j.issn.1000-5048.20200212

Journal of China Pharmaceutical University > 2020 > 51(2): 206-212. > DOI: 10.11665/j.issn.1000-5048.20200212

GAO Qi, HAN Yue, XU Wei, XU Jingjing, WANG Min, ZHANG Juan. Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models[J]. Journal of China Pharmaceutical University, 2020, 51(2): 206-212. DOI: 10.11665/j.issn.1000-5048.20200212

Citation:

PDF (4168 KB)

Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models

More Information

Graphical Abstract

Abstract

Abstract

This study aimed to investigate the antitumor efficacy of a single-chain variable fragment JZC00 combined with 2-deoxyglucose(2-DG)on murine non-small lung cancer cell and breast cancer cell models. JZC00 was expressed by E. coli and identified using SDS-PAGE and Western blot. The combination inhibited the proliferation of LLC and 4T1 cells. The concentration of glucose and lactic acid in the medium were determined by glucose and lactate kit, respectively, then calculated the tumor cell glucose uptake inhibition rate and lactate release inhibition rate. In vivo, the tumor volume and tumor weight were analyzed after 15-day treatment. The results showed that the molecular weight of JZC00 expressed was correct, and it could inhibit the proliferation of tumor cells in vitro. JZC00 and 2-DG could inhibit the glycolysis of tumor cells, respectively, and JZC00 combined with 2-DG could inhibit glycolysis synergistically. When hypoxic microenvironment was induced in vitro, the inhibition of glycolysis by JZC00 treatment decreased. However, it was reversed with the addition of 2-DG. The in vivo models the combination showed a significantly improved tumor suppressive effect compared with JZC00 treated group, suggesting that 2-DG could improve the anti-tumor effect of anti-angiogenic antibodies and its combination has the potentialial value in the treatment of solid tumors.
- single-chain antibody,
- 2-deoxyglucose,
- glycolysis,
- tumor

FullText(HTML)

References (19)

References

[1]	Zhang WL,Wang XY,Yan F.Advances of relationship between protein O-GlcNAcylation and glucose metabolism in tumors[J].J China Pharm Univ(中国药科大学学报),2019,50(2):7-14.
[2]	Kuczynski EA,Ermeulen PB,Pezzella F,et al.Vessel co-option in cancer[J].Nat Rev Clin Oncol,2019,16(8):469-493.
[3]	Ferrara N,Kerbel RS.Angiogenesis as a therapeutic target[J].Nature,2005,438(7070):967-974.
[4]	Carmeliet P,Jain RK.Molecular mechanisms and clinical applications of angiogenesis[J].Nature,2011,473(7347):298-307.
[5]	Roskoski R.Vascular endothelial growth factor(VEGF)signaling in tumor progression[J].Crit Rev Oncol Hematol,2007,62(3):179-213.
[6]	Simon T,Gagliano T,Giamas G.Direct effects of anti-angiogenic therapies on tumor cells:VEGF signaling[J].Trends Mol Med,2017,23(3):282-292.
[7]	Fuchs CS,Tabernero J,Tomásek J,et al.Biomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumab[J].Br J Cancer,2016,115(8):974-982.
[8]	Allen E,Jabouille A,Rivera LB,et al.Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation[J].Sci Transl Med,2017,9(385):eaak9679.
[9]	Urakami K, Zangiacomi V, Yamaguchi K, et al. Impact of 2-deoxy-D-glucose on the target metabolome profile of a human endometrial cancer cell line[J].Biomed Res,2013,34(5):221-229.
[10]	Zaira L,Wiek P,Valeriya D,et al.2-Deoxy-D-glucose restore glucocorticoid sensitivity in acute lymphoblastic leukemia via modification of N-Linked glycosylation in an oxygen tension-independent manner[J].Oxid Med Cell Longev,2017,2017:1-15.
[11]	Zagorodna O,Martin SM,Rutkowski DT,et al.2-Deoxyglucose-induced toxicity is regulated by Bcl-2 family members and is enhanced by antagonizing Bcl-2 in lymphoma cell lines[J].Oncogene,2012,31(22):2738-2749.
[12]	Golding JP, Wardhaugh T, Patrick L, et al. Targeting tumour energy metabolism potentiates the cytotoxicity of 5-aminolevulinic acid photodynamic therapy[J].Br J Cancer,2013,109(4):976-982.
[13]	Zhang SQ,Yung KLK,Chung SK,et al.Aldo-Keto reductases mediated cytotoxicity of 2-deoxyglucose:a novel anticancer mechanism[J].Cancer Sci,2018,109:1970-1980.
[14]	Huang CC,Wang S,Lin LL,et al.Glycolytic inhibitor 2-deoxyglucose simultaneously targets cancer and endothelial cells to suppress neuroblastoma growth in mice[J].Dis Model Mech,2015,8(10):1247-1254.
[15]	Zhang J,Li H,Wang X,et al.Phage-derived fully human antibody scFv fragment directed against human vascular endothelial growth factor receptor 2 blocked its interaction with VEGF[J].Biotechnol Progr,2012,28(4):981-989.
[16]	Xie W,Li D,Zhang J,et al.Generation and characterization of a novel human IgG1 antibody against vascular endothelial growth factor receptor 2[J].Cancer Immunol Immunother,2014,63(9):877-888.
[17]	Sun Q,Chen X,Ma J,et al.Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth[J].Proc Natl Acad Sci U S A,2011,108(10):4129-4134.
[18]	Rapisarda A,Melillo G.Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia[J].Nat Rev Clin Oncol,2012,9(7):378-390.
[19]	Zhao Y,Liu H,Liu Z,et al.Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism[J].Cancer Res,2011,71(13):4585-4597.

[1]	LIU Li, PEI Siran, WU Huali, ZHAO Qingshun, PENG Jixian, SHANG Jing. Drug screening model of treating pigmentation disorders in tyrp1a transgenic zebrafish[J]. Journal of China Pharmaceutical University, 2016, 47(6): 740-743. DOI: 10.11665/j.issn.1000-5048.20160618
[2]	SHAO Xin, YI Qianying, YANG Chunlei. Discovery of novel EphB4 inhibitors based on pharmacophore modeling and virtual screening techniques[J]. Journal of China Pharmaceutical University, 2016, 47(1): 38-47. DOI: 10.11665/j.issn.1000-5048.20160105
[3]	HE Hua, ZHANG Xue, WANG Yuhao, LIU Xiaoquan. Advances in pharmacokinetic and pharmacodynamic modeling of monoclonal antibody[J]. Journal of China Pharmaceutical University, 2015, 46(3): 279-288. DOI: 10.11665/j.issn.1000-5048.20150304
[4]	TANG Chunlei, HUANG Wenlong, QIAN Hai. Construction and application of 3D-pharmacophore model of glucokinase agonists[J]. Journal of China Pharmaceutical University, 2015, 46(2): 181-187. DOI: 10.11665/j.issn.1000-5048.20150208
[5]	HE Xiaobei, LIU Xiaodong. Physiologically based pharmacokinetic model of mechanism-based inhibition of theophylline/caffeine by enoxacin/ciprofloxacin[J]. Journal of China Pharmaceutical University, 2013, 44(1): 77-84. DOI: 10.11665/j.issn.1000-5048.20130113
[6]	REN Xin-yi, CHEN Yuan-cheng, WANG Yan, XIAO Yuan-yuan, LIU Xiao-quan. Pharmacokinetic-pharmacodynamic(PK-PD) modeling of salvianolic acid A on the plasma homocysteine in rats[J]. Journal of China Pharmaceutical University, 2012, 43(3): 260-265.
[7]	Linear Model for Prediction of Drug Shelf Life[J]. Journal of China Pharmaceutical University, 1999, (2): 69-72.
[8]	Yang Jinghua, Song Xiangzheng. The Markovian Model C in Pharmacokinetics[J]. Journal of China Pharmaceutical University, 1997, (1): 59-62.
[9]	Animal ECG Automatic Sample and Analysis-process by Computer[J]. Journal of China Pharmaceutical University, 1995, (5): 304-307.
[10]	Computer Program for the Effect Parameters of Combined Pharmacokinetic and Pharmacodynamic Model[J]. Journal of China Pharmaceutical University, 1990, (3): 142-146.

Cited By

Get Citation

PDF

XML

Article views (372) PDF downloads (772)

Turn off MathJax

Article Contents

Abstract

References

Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models

Abstract

References

Related Articles

Catalog

Combination of a single-chain variable fragment JZC00 with 2-deoxyglucose inhibited tumor growth in murine models

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content